Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study

Efficacy and safety of TQB2450 combined with anlotinib as maintenance therapy for LS-SCLC after definitive concurrent or sequential chemoradiotherapy: a prospective phase Ib study

Abstract Purpose There is a significant unmet need in treating patients with limited-stage small-cell lung cancer (LS-SCLC). The ETER701 study showed that Benmelstobart (TQB2450, an anti-PD-L1 antibody) combined with Anlotinib and chemotherapy achieved the longest progression-free survival (PFS) and...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoli Liu, Xiaoyan Yin, Lulu Zhuang, Junxu Wen, Zhonghui Wei, Wenxing Cui, Minghao Yu, Kaikai Zhao, Lanping Liu, Lingling Kong, Liyang Jiang, Xuquan Jing, Hui Zhu, Xunqiang Wang, Xinjun Dong, Jinming Yu, Xiangjiao Meng
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Cancer
Subjects:
Limited-stage small cell lung cancer
Combined drug therapy
Anlotinib
TQB2450
Efficacy
Safety
Online Access:https://doi.org/10.1186/s12885-025-13885-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13885-8

Similar Items